Autoplaque vs Cleerly ISCHEMIA

Direct competitors — feature-level head-to-head below. Comparability 80/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Autoplaque

by Cedars-Sinai Medical Center: AIM

Cleerly ISCHEMIA

by Cleerly

AI Verdict

These tools are highly comparable as both are FDA-cleared AI solutions that analyze CT angiography images for coronary plaque and stenosis assessment in heart disease. Autoplaque focuses on quantitative plaque analysis for risk prediction, while Cleerly ISCHEMIA further provides non-invasive fractional flow reserve (FFR) estimation to determine the likelihood of vessel-level ischemia. This makes them direct competitors, with Cleerly ISCHEMIA offering an additional functional assessment layer.

Choose Autoplaque if…

Choose Autoplaque if your primary need is detailed, quantitative analysis of coronary plaque and luminal stenoses directly from CT angiography images. This workstation-based software is ideal for clinicians requiring precise measurements and characterization of atherosclerotic plaque, with the flexibility to review and edit automated segmentations for accurate heart attack risk prediction and treatment guidance.

View Autoplaque →

Choose Cleerly ISCHEMIA if…

Choose Cleerly ISCHEMIA if you require a non-invasive assessment of coronary artery ischemia likelihood at a vessel level, alongside comprehensive plaque characterization. This web-based AI tool is particularly beneficial for physicians seeking to integrate fractional flow reserve (FFR) estimation and detailed interactive reports into personalized diagnosis and treatment planning for heart disease.

View Cleerly ISCHEMIA →

When choosing between Autoplaque and Cleerly ISCHEMIA, physicians should consider their primary focus in cardiac CT angiography (CCTA) analysis. Autoplaque excels in detailed quantitative analysis of coronary plaques and luminal stenoses directly from CT images, providing measurements of vessel diameter and area, and allowing for clinician review and editing of automated segmentations. This makes it particularly suited for practices prioritizing in-depth morphological assessment of plaque burden and stenosis severity for heart attack risk prediction and treatment guidance.

In contrast, Cleerly ISCHEMIA focuses on non-invasively determining the likelihood of coronary artery ischemia at a vessel level, leveraging AI to estimate fractional flow reserve (FFR) and characterize plaque in terms of volume, type, and location. The key practical difference lies in their deployment and output: Autoplaque is a workstation-based software providing direct image analysis tools, while Cleerly ISCHEMIA is a web-based platform delivering comprehensive interactive reports and 3D digital models of coronary arteries. Therefore, a physician primarily interested in detailed plaque morphology and direct control over image segmentation might lean towards Autoplaque. Conversely, a physician prioritizing an AI-driven assessment of ischemia likelihood and comprehensive, web-based reporting for personalized diagnosis and treatment planning may find Cleerly ISCHEMIA more aligned with their needs.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Autoplaque	Cleerly ISCHEMIA
Pricing	Not disclosed	Contact for details
Deployment	Workstation-based software, runs on Windows or Mac computer platforms	Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance)
FDA Status	1 AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Cleerly ISCHEMIA

Cleerly ISCHEMIA's web-based platform with comprehensive interactive reports and API integration generally offers superior accessibility and workflow integration in a modern clinical setting. In contrast, Autoplaque's workstation-based deployment might require more localized IT management.

Clinical Value

Cleerly ISCHEMIA

While both are FDA-cleared for CCTA analysis, Cleerly ISCHEMIA provides non-invasive fractional flow reserve (FFR) estimation and vessel-level ischemia likelihood determination. This functional assessment offers a more direct and comprehensive understanding of disease significance beyond just anatomical plaque analysis, aiding in more precise treatment planning.

Pricing & Value

Tie

Both Autoplaque and Cleerly ISCHEMIA lack transparent pricing information, making a direct comparison of their cost-effectiveness impossible. Although Cleerly mentions its data transfer proxy is provided without additional charge, this minor detail is insufficient to declare a clear winner in overall pricing and value.

Enterprise Readiness

Cleerly ISCHEMIA

Cleerly ISCHEMIA explicitly states it is HIPAA compliant and offers a Business Associate Agreement (BAA), which are critical for enterprise adoption in healthcare. Its web-based deployment with a data transfer proxy also suggests a more scalable and manageable solution for large organizations compared to Autoplaque's workstation-based approach and unspecified compliance.

Innovation

Cleerly ISCHEMIA

Cleerly ISCHEMIA demonstrates greater innovation by incorporating non-invasive fractional flow reserve (FFR) estimation and vessel-level ischemia likelihood determination. This capability moves beyond purely anatomical assessment to provide crucial functional insights, representing a more advanced application of AI in cardiology.

Support & Docs

Tie

Neither the provided structured facts nor readily available public information offers specific details regarding the level of support or documentation for Autoplaque or Cleerly ISCHEMIA. Without this crucial information, it is impossible to distinguish between the two tools in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Autoplaque	Cleerly ISCHEMIA
Name	Autoplaque	Cleerly ISCHEMIA
Company	Cedars-Sinai Medical Center: AIM	Cleerly
Tagline	AI-Powered Quantitative Analysis for Coronary Plaque and Stenosis	AI-Powered Precision for Non-Invasive Ischemia Detection
Primary Analysis Focus	Quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance.	Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease.
Plaque Characterization	AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician)	Coronary plaque characterization (volume, type, location); 3D digital models of coronary arteries
Stenosis Assessment	Measurement of luminal stenoses; Measurement of vessel diameter and area	Stenosis severity assessment
Ischemia Detection Capability	Not specified	Non-invasive fractional flow reserve (FFR) estimation; Vessel-level ischemia likelihood determination

Videos

Demos, reviews, and walkthroughs featuring Autoplaque and Cleerly ISCHEMIA.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary difference in clinical utility between Autoplaque and Cleerly ISCHEMIA?

Autoplaque is designed for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. Cleerly ISCHEMIA analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, in addition to coronary plaque characterization and stenosis severity assessment.

Does either tool provide non-invasive functional assessment like FFR estimation?

Cleerly ISCHEMIA offers non-invasive fractional flow reserve (FFR) estimation and vessel-level ischemia likelihood determination. Autoplaque focuses on quantitative morphological analysis of plaque and stenosis and does not list FFR estimation as a feature.

What are the differences in data security and compliance features?

Cleerly ISCHEMIA explicitly states it has a Business Associate Agreement (BAA) and is HIPAA compliant. Autoplaque's provided information does not specify whether it has a BAA or is HIPAA compliant.

What kind of reporting and integration capabilities do these tools offer?

Cleerly ISCHEMIA provides comprehensive interactive web-based reports and integrates with PowerScribe via API. Autoplaque is a workstation-based post-processing application that allows for automated vessel, plaque, and lumen segmentation which is reviewable and editable by the clinician, and offers review in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views.

How do the approaches to plaque analysis differ?

Autoplaque provides AI-powered quantitative analysis of atherosclerotic plaque, including detection, characterization, and measurement of luminal stenoses, with automated segmentation that is reviewable and editable by a clinician. Cleerly ISCHEMIA also performs coronary plaque characterization (volume, type, location) and stenosis severity assessment, generating 3D digital models of coronary arteries.

Are there differences in the level of clinician interaction with the AI outputs?

Autoplaque features automated vessel, plaque, and lumen segmentation that is reviewable and editable by the clinician. Cleerly ISCHEMIA provides comprehensive interactive web-based reports and 3D digital models, with the Cleerly ISCHEMIA Index being a binary indication of likely ischemia presence or absence.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Autoplaque or Cleerly ISCHEMIA

Backers

Who funded each tool's parent company.